REPONEX PHARMACEUTICALS A/S: Financial statements 2022
CVR: 30082346
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -10,209,830 compared with DKK -9,883,156 the year before. Equity in the 2022 report amounted to DKK 17,378,706. The solvency ratio was 87%.
- Profit/Loss
- DKK -10,209,830
- Equity
- DKK 17,378,706
- Total Assets
- DKK 19,984,287
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -10.2M | 17.4M | - |
| 2021 | 0 | 0 | -9.9M | 27.4M | - |
| 2020 | 0 | 0 | -1.5M | 13.4M | - |
| 2019 | 0 | 0 | -1.9M | 14.9M | - |
| 2018 | 0 | 0 | -1.3M | 2.4M | - |
Official annual report
Keep an eye on REPONEX PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of October 11, 2022, Christian Vinding Thomsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of October 11, 2022, Sigbjørn Georg Nielsen Kjærgård has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of October 11, 2022, Sigbjørn Georg Nielsen Kjærgård is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of October 11, 2022, Klaus Snej Jensen has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of October 10, 2022, Christian Vinding Thomsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of October 10, 2022, Sigbjørn Georg Nielsen Kjærgård has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -9,883,156.
As of March 1, 2022, Thomas Kaas Selsø is registered as director of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.